CN109602817A - A kind for the treatment of is reduced the Chinese medicine composition of caused osteoporosis by estrogen - Google Patents
A kind for the treatment of is reduced the Chinese medicine composition of caused osteoporosis by estrogen Download PDFInfo
- Publication number
- CN109602817A CN109602817A CN201910146734.3A CN201910146734A CN109602817A CN 109602817 A CN109602817 A CN 109602817A CN 201910146734 A CN201910146734 A CN 201910146734A CN 109602817 A CN109602817 A CN 109602817A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- fructus lycii
- achyranthis bidentatae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of Chinese medicine composition of prevention and treatment osteoporosis caused by estrogen reduction, and the Chinese medicine composition is made of each bulk pharmaceutical chemicals of following parts by weight: red stilbene 6-30 parts, 3-35 parts of Rehmannia glutinosa, 3-35 parts of the fruit of glossy privet, 3-35 parts of fructus lycii and 3-35 parts of radix achyranthis bidentatae.The present invention also provides corresponding preparation method and Chinese materia medica preparations.Chinese medicine composition and its preparation of the invention is used without compatibility other drugs, can effectively be prevented and treated and be reduced various symptoms caused by causing osteoporosis as estrogen, significant in efficacy, drug is at low cost.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicine preparation, and in particular to a kind for the treatment of osteoporosis caused by estrogen reduction
Chinese medicine composition of disease and its preparation method and application.
Background technique
Osteoporosis (osteoporosis, OP) alias osteoporosis, it is the generalized bone that a variety of causes cause
A kind of sign that ingredient is cut down, i.e. systemic skeletal disease show that systemic sclere generates calcification, under normal conditions with bone
Micro-structure, which generates damaged, bone brittleness, has the tendency that growth is a kind of bone metabolism disease of characteristic.Osteoporosis is pressed
It is divided into primary osteoporosis according to the cause of disease and secondary osteoporosis is these two types of, clinical manifestation is often pain.Post menopausal woman
Female's osteoporosis and senile osteoporosis are divided into primary osteoporosis, and such case is very common.Osteoporosis
The typically no special clinical manifestation of patient, but a systems such as bow-backed, respiratory function decline, fracture can be generated under serious situation
Column clinical picture generates certain puzzlement to people's lives.And osteoporosis is aggravated with nowadays aging society,
Its disease incidence increasingly increases, and brought economic society burden is also gradually deepened significantly, it is necessary to cause being vigilant for people.The disease
Mainstay has calcium agent, estrogen, calcitonin, fluoride preparation etc. in terms of western medical treatment, but exists with very big side effect
Or curative effect it is not significant a series of problems, such as.Since Chinese medicine has the characteristics that integration of drinking and medicinal herbs, there is popularity and hypotoxicity, so its
A series of side effects caused by chemical drugs can be effectively avoided when treating disease, clinical practice experiment also turns out some Chinese medicines
Compound or folk prescription have more apparent therapeutic effect for osteoporosis.Therefore, a kind of treat is developed to be led by estrogen reduction
Causing the tcm product of osteoporosis has very big market prospects.
Summary of the invention
In order to solve the problems in the existing technology, the present invention provides one kind uses without compatibility other drugs, treats
Imitate can treat reduced by estrogen caused by osteoporosis Chinese medicine composition, the present invention also provides preparation method and
Using.
The present invention provides a kind of Chinese medicine composition for the treatment of osteoporosis caused by estrogen reduction, the Chinese medicine group
It closes object to be made of each bulk pharmaceutical chemicals of following parts by weight: red stilbene 6-30 parts, 3-35 parts of Rehmannia glutinosa, 3-35 parts of the fruit of glossy privet, fructus lycii 3-35
Part, 3-35 parts of radix achyranthis bidentatae.
Preferably, the Chinese medicine composition is made of each bulk pharmaceutical chemicals of following parts by weight: red stilbene 12-26 parts, Rehmannia glutinosa
9-13 parts, 9-13 parts of the fruit of glossy privet, 9-13 parts of fructus lycii and 9-13 parts of radix achyranthis bidentatae；
Preferably, the Chinese medicine composition is made of each bulk pharmaceutical chemicals of following parts by weight: 17 parts of red stilbene, Rehmannia glutinosa 10
Part, 10 parts of the fruit of glossy privet, 10 parts of fructus lycii, 10 parts of radix achyranthis bidentatae.
The present invention also provides the preparation methods of above-mentioned Chinese medicine composition, weigh red stilbene, Rehmannia glutinosa, female respectively by weight ratio
Loyal son, fructus lycii and radix achyranthis bidentatae mixing, are added 8-20 times of the total weight water measured, decoct and extract 2-4 times, extract 1-2 hours every time, close
And decoction liquor, filtration collect filtrate, are concentrated into the medicinal extract of relative density 1.26-1.35.
The present invention also provides the preparation methods of above-mentioned Chinese medicine composition pill, comprising the following steps:
(1) fruit of glossy privet, the crushing of red stilbene for weighing formula ratio, obtain fine powder；
(2) Rehmannia glutinosa, fructus lycii and the radix achyranthis bidentatae for separately weighing formula ratio, after mixing, are added the water that 8-20 times of its total weight is measured,
It decocts and extracts 2-4 times, extract 1-2 hours every time, merge decoction liquor, filtration collects filtrate, supernatant is taken to be concentrated under reduced pressure into relatively
The medicinal extract of density 1.26-1.35；
(3) fine powder that step (1) obtains and the medicinal extract that step (2) obtains are uniformly mixed, press strip, pill, 80 DEG C or less
It is dry, polishing.
The medicine of osteoporosis caused by being reduced in preparation treatment by estrogen the present invention also provides above-mentioned Chinese medicine composition
Application in object.
The present invention also provides a kind of Chinese materia medica preparation, effective component is Chinese medicine composition of any of claims 1 or 2.
Preferably, the Chinese materia medica preparation further includes pharmaceutically acceptable auxiliary material.
Preferably, the auxiliary material includes diluent, adhesive, the diluent be starch, dextrin, lactose, maltose,
One or more of microcrystalline cellulose and mannitol；Described adhesive is water or ethyl alcohol.
Preferably, the auxiliary material further includes lubricant or preservative, the lubricant is talcum powder, superfine silica gel powder and hard
One or more of fatty acid magnesium, the preservative are sodium benzoate, potassium sorbate, dehydroactic acid sodium, calcium propionate, diacetic acid
One or more of sodium, sodium lactate, propylparaben, nisin.
Preferably, the dosage form of the Chinese materia medica preparation is granule, capsule, tablet, pill or liquid preparation.
Wherein, red stilbene is sweet, tepor.With tonifying Qi and lifting yang, strengthening exterior and reducing sweat, inducing diuresis for removing edema, shengjin nourishing, move stagnation and palsy,
The effect of pus draining and toxin expelling, expelling pus and promoting granulation.For deficiency of vital energy and acking in strength, anorexia and loose stool, the sinking of qi of middle-jiao, rush down prolapse of the anus for a long time, uterine bleeding of having blood in stool, exterior deficiency
Spontaneous perspiration, deficiency of vital energy and edema, Heat Diabetes, blood deficiency chlorosis, hemiplegia, numbness pain is numb, ulcer is difficult to burst, burst for a long time and does not holds back.Its pharmacology is living
Property mainly has immunological regulation, antitumor, anti-oxidant, hypoglycemic, anti-osteoporosis etc..
Rehmannia glutinosa, it is sweet in flavor, warm-natured, return liver and kidney channel.With enrich blood moist, the effect of beneficial to spirit and marrow.For blood deficiency chlorosis,
Dizziness palpitaition, liver-kidney Yin deficiency, hectic fever night sweat, impotence of passing out semen, infertility, irregular menstruation, metrostaxis, soreness and weakness of waist and knees, tinnitus
Deafness, dim-sighted, poliosis is quenched one's thirst, constipation, a series of symptoms such as kidney deficiency characterized by dyspnea.Modern pharmacological studies have shown that it has
The effects of heart tonifying, diuresis, hypoglycemic and raising peripheral leukocytes, enhancing immune function.
Fructus lycii property sweet and neutral, returns liver and kidney channel.With nourishing liver and kidney, the effect of benefiting shrewd head.For kidney deficiency and liver, essence and blood is lost
The symptoms such as the vertigo of void, hypopsia, the soreness and weakness of waist and knees of the deficiency of liver-yin and kidney-yin are passed out semen, and the deficiency of Yin is quenched one's thirst.The research of modern pharmacology
Show that fructus lycii has various pharmacological actions, can such as enhance non-specific immune function, improve disease resistance, inhibits swollen
Tumor growth and cell mutation；It is closely related with Apoptosis, the phagocytic function of phagocyte can be significantly improved, lymphocyte is improved
Proliferative capacity；Also have the function of apparent reducing blood lipid, adjust lipid metabolism, to prevention cardiovascular disease have positive effect with
And hypoglycemic, blood pressure effect, enhance hematopoiesis function, liver protection and oxidation resistant effect.
Fruit of glossy privet sweet, bitter, cold.With nourishing liver and kidney, the effect of improving eyesight black hair.For the deficiency of liver-yin and kidney-yin, dizziness and tinnitus, waist
Knees soreness, poliosis, mesh is secretly unknown, Heat Diabetes, osteopyrexia and fever.Modern pharmacological studies have shown that having liver protection immunoregulatory
Effect, can anti-oxidant, anti-aging, antitumor, also have the function of hypoglycemic, reducing blood lipid.
Radix achyranthis bidentatae bitter, acid, it is mild-natured.With promoting blood circulation to remove blood stasis, clearing damp diuresis, clearing heat and detoxicating effect.For controlling stranguria syndrome, urinate
Blood, women's menostasis, abdominal mass, rheumatic arthritis, tinea pedis, oedema, dysentery, malaria, diphtheria, carbuncle swells, traumatic injury.Modern pharmacology is ground
It is studied carefully with systems such as good decompression, hypoglycemic, anti-hepatic fibrosis, enhancing cell activity, enhancing humoral immunity, anti-inflammatory anti-agings
Column effect.
Fang Zhong, red stilbene have the function of tonifying Qi and lifting yang, tonifying middle-Jiao and Qi；There is radix rehmanniae preparata enriching yin of enriching blood, beneficial to spirit and marrow to be used；Female
Loyal son being capable of nourishing liver and kidney, improving eyesight black hair；Fructus lycii has the function of warming kidney and enhancing yang, benefiting shrewd head；Radix achyranthis bidentatae has promoting blood circulation to remove blood stasis, dispels
Wet diuresis is used.Pharmacology knowledge and mutual synergistic effect based on above-mentioned gomi herbs, are combined use to prepare one
Kind have effects that nourishing liver and kidney, warming kidney and enhancing yang, beneficial to spirit and marrow, tonifying middle-Jiao and Qi, promoting blood circulation to remove blood stasis Chinese medicine composition.
Bulk pharmaceutical chemicals are selected by the method for rats with bilateral removal ovary operation modeling.
By 3 monthly ages sexal maturity SD female rats 60, every rat body weight about 200g, at random by rat be divided into A, B, C, D,
E, F6 group, each group 10.A group is prescription one (17 parts of red stilbene, 17 parts of oyster, 17 parts of Herba Epimedii, 17 parts of Radix Angelicae Sinensis), and B group is place
Two (17 parts of red stilbene, 15 parts of radix achyranthis bidentatae, 15 parts of Cortex Eucommiae, 15 parts of Morinda officinalis, 15 parts of psoralea corylifolias) of side, C group are (the red stilbene 17 of prescription three
Part, 10 parts of radix rehmanniae preparata, 10 parts of the fruit of glossy privet, 10 parts of fructus lycii, 10 parts of radix achyranthis bidentatae), D group is model group, and E group is positive drug group, F group is false
Operation group.Each prescription group weighs medicinal material mixing according to recipe quantity, and the water measured with 10 times decocts 3 times, preceding 1.5 small every time twice
When, third time 1 hour merges filtrate three times, is concentrated to get Chinese medicine composition.After rat is got, adaptive feeding is needed 1 week.
A, B, C, D, E group prepare osteoporosis model after a week, by its two sides ovariectomy after rat is anesthetized with ether.F group is just
Normal control group rejects ovary beside portions adipose tissue that is, after the lower end tubal ligation of plum blossom sample ovary, keeps ovary
Completely.After modeling operation, divide basket at 6 cages rat, guarantee that every group of rat body weight mean is at the same level, gives chow diet and feed 3
It, the 4th day formally starts to be administered.F group (sham-operation group), D group (model group) are daily with the dosage of 10ml/kg with physiological saline
Stomach-filling；A, B, C group daily stomach-filling by weight of primary crude drug amount；Positive controls use chemical drugs Estradiol Valerate, with
0.2mg/kg·d-1The daily stomach-filling of dosage.Gastric infusion is continued for three months, every two weeks weighed rat body weight, for adjusting
Dose terminates until stomach-filling.
After gastric infusion three months, all rats are anaesthetized in the method that 0.3% valeric acid barbital sodium is injected intraperitoneally, fiber crops
Mouse lain low after liquor-saturated be placed in dual intensity X borne densitometers measurement rat body bone density (Bone mineral Density,
BMD)；Mouse is put to death in etherization later, takes out complete Rat Right femur, rubs the meat fiber for going the attachment on side with the hands with gauze
Tissue, exposes clean bone structure, the right femoral bmd of this 60 rats is measured with dual intensity X borne densitometers.
Experimental result is shown in Table 1.
Table 1
1) the P < 0.05 compared with blank group；2) the P < 0.05 compared with model group.
As shown in Table 1, model group removal ovary causes osteoporosis rat to have compared with other each group whole bodies and right thighbone density bright
Aobvious decline illustrates modeling success compared with there is apparent difference (P < 0.05) for its blank group.For whole body bone density, A
Group and C group, positive drug group have significant difference compared with model group, and B group is compared compared with model group and is not statistically significant.About
Right femoral bmd, through A group, B group gastric infusion Rat Right femoral bmd and model group between without apparent difference, C
Though the group right femoral bmd of castrated rats is apparently higher than model group not as good as positive drug group.In conclusion red stilbene be monarch drug in a prescription not
Good treatment is all had in terms of increasing Ovariectomized Rats whole body and right femoral bmd in varying degrees with prescription
Effect is especially obvious (17 parts of red stilbene, 10 parts of radix rehmanniae preparata, 10 parts of the fruit of glossy privet, 10 parts of fructus lycii, 10 parts of radix achyranthis bidentatae) with C group effect.
The result of table 1 further illustrates Chinese medicine composition of the invention, to osteoporosis caused by being reduced by estrogen
With preferable therapeutic effect.
Chinese medicine composition of the invention can be treated effectively reduced by estrogen caused by osteoporosis, when use is nontoxic
Side effect is not necessarily to and other drugs compatible use.
The present invention is by being made Modern preparations: granule, capsule, tablet, pill or liquid preparation improve Chinese medicine
Utilization rate, makes that product dosage is accurate, dissolution is rapid, in good taste, carries and saves convenient, property and stablize.
The various raw materials of the present invention and auxiliary material are common raw materials in the market, cheap, and preparation of the present invention
Method is simple and easy, is easy to large-scale industrial production.
Specific embodiment
Embodiment below facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiments
Method is unless otherwise specified conventional method.Test material as used in the following examples is unless otherwise specified city
It sells.In the present invention, described " part " refers both to parts by weight.
The Chinese medicine composition of osteoporosis caused by treatment of the invention is reduced by estrogen, is calculated by weight as:
Red stilbene 6-30 parts, 3-35 parts of Rehmannia glutinosa, 3-35 parts of the fruit of glossy privet, 3-35 parts of fructus lycii, 3-35 parts of radix achyranthis bidentatae.
It further include auxiliary material, such as diluent, anti-corrosion when preparing granule, capsule, tablet, pill or liquid preparation
Agent, adhesive, PEG6000, corrigent and lubricant etc..
Wherein, the diluent can be one in starch, dextrin, lactose, maltose, microcrystalline cellulose and mannitol
Kind is several；The preservative can for sodium benzoate, potassium sorbate, dehydroactic acid sodium, calcium propionate, sodium Diacetate, sodium lactate,
One or more of propylparaben, nisin；Described adhesive can be water or ethyl alcohol；The lubrication
Agent can be one or more of talcum powder, superfine silica gel powder and magnesium stearate.
Diluent is preferably starch and/or lactose；
Preservative is preferably sodium benzoate；
Adhesive preferred alcohol；
The preferred magnesium stearate of lubricant.
Treatment of the invention by estrogen reduce caused by osteoporosis Chinese medicine composition the preparation method comprises the following steps:
It weighs red stilbene, Rehmannia glutinosa, the fruit of glossy privet, fructus lycii and radix achyranthis bidentatae raw material respectively by weight ratio, adds into above-mentioned raw materials
Enter the water that 8-20 times of its total weight is measured, decoct and extract 2-4 times, extract 1-2 hours every time, merge decoction liquor, filter is collected in filtration
Liquid.The filtrate of Chinese medicine composition obtained above is stood 12-24 hours, supernatant is taken to be concentrated under reduced pressure into relative density 1.26-
1.35 medicinal extract.
Treatment of the invention by estrogen reduce caused by osteoporosis herbal mixture particle the preparation method comprises the following steps:
(1) the above-mentioned concentrated extract being prepared is obtained into extract powder in 60-80 DEG C of crushed after being dried；
(2) then the extract powder for obtaining step (1) and diluent and adhesive are dried by said ratio mixing granulation；
Wherein, diluent is to be added before mixing granulation into extract powder, and adhesive is added in pelletization, Granulation time
It is 15-60 minutes.
Treatment of the invention by estrogen reduce caused by osteoporosis herbal mixture capsule the preparation method comprises the following steps:
The herbal mixture particle of osteoporosis caused by being reduced through treatment made from the above method by estrogen, mistake
20-50 mesh, according to common process encapsulating capsule.
Treatment of the invention by estrogen reduce caused by osteoporosis herbal mixture tablet the preparation method comprises the following steps:
(1) the above-mentioned concentrated extract being prepared is obtained into extract powder in 60-80 DEG C of crushed after being dried；
(2) extract powder for obtaining step (1) and diluent and adhesive are according to said ratio mixing granulation 15-60 points
Then clock is dried, 10-50 mesh sieve, and lubricant, tabletting is added.Diluent is to be added before mixing granulation into extract powder
, adhesive is added in pelletization.
Treatment of the invention by estrogen reduce caused by osteoporosis herbal mixture condensed pill the preparation method comprises the following steps:
(1) fruit of glossy privet total amount, the crushing of red stilbene total amount are weighed, net is sieved with 100 mesh sieve, obtains fine powder, sterilize.
(2) Rehmannia glutinosa, fructus lycii and radix achyranthis bidentatae raw material total amount are separately weighed, 8-20 times of its total weight is added into above-mentioned raw materials and measures
Water, decoct extract 2-4 time, every time extract 1-2 hour, merge decoction liquor, filtration, collection filtrate, filtrate standing 12-24 it is small
When, take supernatant to be concentrated under reduced pressure into the medicinal extract of relative density 1.26-1.35.
(3) fine powder that step (1) obtains and the medicinal extract that step (2) obtains are uniformly mixed, press strip, pill, in 80 DEG C with
Lower drying, polishing to obtain the final product.
Traditional Chinese drug inspissation ball preparation process are as follows: the extraction of drug dispensing taste is condensed into medicinal extract in the middle part of prescription, and part flavour of a drug break into fine powder, will
Medicinal extract and fine powder are uniformly mixed, pill.If being that extract powder viscosity is too big entirely, can not pill, if being that fine powder can not be bonded in one entirely
Play pelletization.Rehmannia glutinosa, fructus lycii are too glutinous in this prescription can not beat fine powder, and radix achyranthis bidentatae is micro- to be not easy to beat fine powder in cutin sample, therefore by glossy privet
Sub and red stilbene all beats fine powder, with Rehmannia glutinosa, fructus lycii, radix achyranthis bidentatae medicinal extract mixing pill.
Treatment of the invention by estrogen reduce caused by osteoporosis herbal mixture pill the preparation method comprises the following steps:
(1) the above-mentioned concentrated extract being prepared is obtained into extract powder in 60-80 DEG C of crushed after being dried；
(2) it takes PEG6000 to heat in oil bath, the extract powder that step (1) obtains is added, being stirred continuously makes whole meltings,
It filters while hot, until instilling in atoleine (outer layer is ice-water bath) condensate liquid in liquid storage bottle and condensing pelletization, suck the liquid sticked
Paraffin to get.
The preparation method of the extract oral liquid preparation of osteoporosis caused by treatment of the invention is reduced by estrogen
Are as follows:
(1) red stilbene, Rehmannia glutinosa, the fruit of glossy privet, fructus lycii and radix achyranthis bidentatae mixing are weighed respectively by weight ratio, its total weight is added
The 8-20 times of water measured is decocted and is extracted 2-4 times, is extracted 1-2 hours every time, and decoction liquor is merged, and filtrate is collected in filtration.
(2) filtrate decompression that step (1) obtains is concentrated into 1000ml, preservative and appropriate corrigent is added, stirs evenly, it is quiet
Set 12 hours, filter, it is filling, sterilizing to get.
Embodiment 1
A kind for the treatment of is reduced the herbal mixture granule of caused osteoporosis by estrogen, by following parts by weight
Raw material is made:
30 parts of red stilbene, 35 parts of Rehmannia glutinosa, 35 parts of the fruit of glossy privet, 35 parts of fructus lycii, 35 parts of radix achyranthis bidentatae, 10 parts of starch, ethyl alcohol 0.6
Part.
The method for preparing above-mentioned particle, comprising the following steps:
30 parts of red stilbene, 35 parts of Rehmannia glutinosa, 35 parts of the fruit of glossy privet, 35 parts of fructus lycii, 35 parts of radix achyranthis bidentatae are weighed, is added into above-mentioned raw materials
Enter the water of 15 times of total weight amounts, decoct and extract 3 times, extract 1.5 hours every time, merges decoction liquor, filtration, it is small that filtrate stands 20
When, it takes supernatant to be concentrated under reduced pressure into the medicinal extract of relative density 1.31, in 70 DEG C of crushed after being dried, obtains extract powder；To above-mentioned leaching
5 parts of mixing granulations of starch are added in cream powder, 0.5 part of ethyl alcohol are added in pelletization, Granulation time is 60 minutes.
Wherein, pelletization of the invention uses common process, such as can use marumerization, squeezes sieving system
Grain, rotation granulation, high speed granulation etc..
Embodiment 2
A kind for the treatment of is led to the Chinese medicine composition of osteoporosis by estrogen reduction, by the raw material system of following parts by weight
: 17 parts of red stilbene, 10 parts of Rehmannia glutinosa, 10 parts of the fruit of glossy privet, 10 parts of fructus lycii, 10 parts of radix achyranthis bidentatae.
The method for preparing above-mentioned Chinese medicine composition, comprising the following steps: weigh 17 parts of red stilbene, 10 parts of Rehmannia glutinosa, the fruit of glossy privet
The water of 15 times of its total weight amounts is added into above-mentioned raw materials for 10 parts, 10 parts of fructus lycii, 10 parts of radix achyranthis bidentatae, decocts extraction 3 times, every time
It extracts 1.5 hours, merges decoction liquor, filtration, filtrate stands 20 hours, supernatant is taken to be concentrated under reduced pressure into the leaching of relative density 1.30
Cream obtains extract powder in 70 DEG C of crushed after being dried.
Embodiment 3
A kind for the treatment of is led to the Chinese medicine composition of osteoporosis by estrogen reduction, by the raw material system of following parts by weight
: 1 part of red stilbene, 1 part of Rehmannia glutinosa, 1 part of the fruit of glossy privet, 1 part of fructus lycii, 1 part of radix achyranthis bidentatae.
The method for preparing above-mentioned Chinese medicine composition, comprising the following steps: weigh 1 part of red stilbene, 1 part of Rehmannia glutinosa, the fruit of glossy privet 1
The water of 12 times of its total weight amounts is added into above-mentioned raw materials for part, 1 part of fructus lycii, 1 part of radix achyranthis bidentatae, decocts and extracts 2 times, extracts 1 every time
Hour, merge decoction liquor, filtration, filtrate stands 12 hours, takes supernatant to be concentrated under reduced pressure into the medicinal extract of relative density 1.35,80
DEG C crushed after being dried, obtains extract powder.
Embodiment 4
A kind for the treatment of is led to the Chinese medicine composition of osteoporosis by estrogen reduction, by the raw material system of following parts by weight
: 6 parts of red stilbene, 3 parts of Rehmannia glutinosa, 3 parts of the fruit of glossy privet, 3 parts of fructus lycii, 3 parts of radix achyranthis bidentatae.
The method for preparing above-mentioned Chinese medicine composition, comprising the following steps: weigh 6 parts of red stilbene, 3 parts of Rehmannia glutinosa, the fruit of glossy privet 3
The water of 10 times of its total weight amounts is added into above-mentioned raw materials for part, 3 parts of fructus lycii, 3 parts of radix achyranthis bidentatae, decocts and extracts 3 times, extracts 1 every time
Hour, merge decoction liquor, filtration, filtrate stands 14 hours, takes supernatant to be concentrated under reduced pressure into the medicinal extract of relative density 1.32,70
DEG C crushed after being dried, obtains extract powder.
Embodiment 5
A kind for the treatment of is led to the Chinese medicine composition of osteoporosis by estrogen reduction, by the raw material system of following parts by weight
: 6 parts of red stilbene, 18 parts of Rehmannia glutinosa, 18 parts of the fruit of glossy privet, 18 parts of fructus lycii, 18 parts of radix achyranthis bidentatae.
The method for preparing above-mentioned Chinese medicine composition, comprising the following steps: weigh 6 parts of red stilbene, 18 parts of Rehmannia glutinosa, the fruit of glossy privet 18
The water of 15 times of its total weight amounts is added into above-mentioned raw materials for part, 18 parts of fructus lycii, 18 parts of radix achyranthis bidentatae, decocts and extracts 3 times, mentions every time
It taking 2 hours, merges decoction liquor, filtration, filtrate stands 16 hours, supernatant is taken to be concentrated under reduced pressure into the medicinal extract of relative density 1.30,
In 60 DEG C of crushed after being dried, extract powder is obtained.
Embodiment 6
A kind for the treatment of is led to the herbal mixture capsule of osteoporosis by estrogen reduction, by the raw material of following parts by weight
It is made:
6 parts of red stilbene, 13 parts of Rehmannia glutinosa, 10 parts of the fruit of glossy privet, 14 parts of fructus lycii, 12 parts of radix achyranthis bidentatae, 4 parts of starch, 0.2 part of ethyl alcohol.
The method for preparing above-mentioned capsule, comprising the following steps:
1) 6 parts of red stilbene, 13 parts of Rehmannia glutinosa, 10 parts of the fruit of glossy privet, 14 parts of fructus lycii, 12 parts of radix achyranthis bidentatae are weighed, into above-mentioned raw materials
The water of 20 times of its total weight amounts is added, decocts and extracts 4 times, extracts 2 hours every time, merges decoction liquor, filtration, it is small that filtrate stands 24
When, it takes supernatant to be concentrated under reduced pressure into the medicinal extract of relative density 1.26, in 60 DEG C of crushed after being dried, obtains extract powder.
2) 4 parts of progress mixing granulations of starch are added in Xiang Shangshu extract powder, 0.2 part of ethyl alcohol are added in pelletization, granulation
Time is 30 minutes.
3) drug granule that granulation obtains is crossed into 50 meshes, according to common process encapsulating capsule.
Embodiment 7
A kind for the treatment of is led to the herbal mixture tablet of osteoporosis by estrogen reduction, by the raw material of following parts by weight
It is made:
It is 24 parts of red stilbene, 35 parts of Rehmannia glutinosa, 30 parts of the fruit of glossy privet, 30 parts of fructus lycii, 30 parts of radix achyranthis bidentatae, 6 parts of starch, 2 parts of lactose, hard
0.2 part of fatty acid magnesium, 0.4 part of ethyl alcohol.
The method for preparing above-mentioned herbal mixture tablet, comprising the following steps:
1) 24 parts of red stilbene, 35 parts of Rehmannia glutinosa, 30 parts of the fruit of glossy privet, 30 parts of fructus lycii, 30 parts of radix achyranthis bidentatae are weighed, into above-mentioned raw materials
The water of 12 times of its total weight amounts is added, decocts and extracts 3 times, extracts 1.5 hours every time, merges decoction liquor, filtration, filtrate stands 16
Hour, it takes supernatant to be concentrated under reduced pressure into the medicinal extract of relative density 1.29, in 65 DEG C of crushed after being dried, obtains extract powder.
2) in Xiang Shangshu extract powder be added 6 parts of starch, 2 parts of lactose carry out mixing granulation together, second is added in pelletization
0.4 part of alcohol, Granulation time is 60 minutes.
3) drug granule for obtaining granulation, with 50 mesh sieves, 0.2 part of stiffened fatty acid magnesium is pressed according to common process
Piece.
Embodiment 8
A kind for the treatment of is led to the herbal mixture condensed pill of osteoporosis by estrogen reduction, by the original of following parts by weight
Material is made:
20 parts of red stilbene, 20 parts of Rehmannia glutinosa, 20 parts of the fruit of glossy privet, 15 parts of fructus lycii, 15 parts of radix achyranthis bidentatae.
The method for preparing above-mentioned condensed pill, comprising the following steps:
1) 20 parts of the fruit of glossy privet, 20 parts of red stilbene crushing are weighed, net is sieved with 100 mesh sieve, obtains fine powder, sterilize.
2) 20 parts of Rehmannia glutinosa, 15 parts of fructus lycii and 15 parts of radix achyranthis bidentatae are weighed, 16 times of its total weight amounts are added into above-mentioned raw materials
Water, decoct extract 3 times, every time extract 1.5 hours, merge decoction liquor, filtration, collect filtrate, filtrate stand 15 hours, take
Clear liquid is concentrated under reduced pressure into the medicinal extract of relative density 1.28.
3) fine powder that step (1) obtains and the medicinal extract that step 2) obtains are uniformly mixed, press strip, pill, in 80 DEG C or less
Dry, polishing to obtain the final product.
Embodiment 9
A kind for the treatment of is led to the Chinese medicine dripping pills of osteoporosis by estrogen reduction, by the raw material system of following parts by weight
:
12 parts of red stilbene, 20 parts of Rehmannia glutinosa, 30 parts of the fruit of glossy privet, 25 parts of fructus lycii, 25 parts of radix achyranthis bidentatae, 20 parts of PEG6000.
The method for preparing above-mentioned Chinese medicine dripping pills, comprising the following steps:
1) 12 parts of red stilbene, 20 parts of Rehmannia glutinosa, 30 parts of the fruit of glossy privet, 25 parts of fructus lycii, 25 parts of radix achyranthis bidentatae are weighed, into above-mentioned raw materials
The water of 15 times of its total weight amounts is added, decocts and extracts 3 times, extracts 2 hours every time, merges decoction liquor, filtration, it is small that filtrate stands 16
When, it takes supernatant to be concentrated under reduced pressure into the medicinal extract of relative density 1.30, in 60 DEG C of crushed after being dried, obtains extract powder.
2) it takes 20 parts of PEG6000 to be heated to about 135 DEG C in oil bath, the extract powder that step (1) obtains is added, constantly stirs
Mixing makes whole meltings, filters while hot, is respectively 9.0mm, 9.8mm with the inside and outside diameter of nozzle until keeping the temperature at 135 DEG C in liquid storage bottle
Water dropper dripping drips fast 80 drops/minute, instills in atoleine (outer layer is ice-water bath) condensate liquid and condense pelletization, inhaled with writing paper made from bamboo
Go the liquid paraffin sticked to get.
Embodiment 10
A kind for the treatment of is led to the herbal mixture oral liquid of osteoporosis by estrogen reduction, by following weight
The raw material of part is made:
18 parts of red stilbene, 15 parts of Rehmannia glutinosa, 20 parts of the fruit of glossy privet, 12 parts of fructus lycii, 9 parts of radix achyranthis bidentatae, 0.1 part of sodium benzoate.
The method for preparing above-mentioned oral liquid, comprising the following steps:
1) 18 parts of red stilbene, 15 parts of Rehmannia glutinosa, 20 parts of the fruit of glossy privet, 12 parts of fructus lycii, 9 parts of radix achyranthis bidentatae are weighed, into above-mentioned raw materials
The water of 10 times of its total weight amounts is added, decocts and extracts 4 times, extracts 2 hours every time, merges decoction liquor, filtration, it is small that filtrate stands 24
When.
2) filtrate decompression that step (1) obtains is concentrated into 1000ml (corresponding 100 parts of water), is added 0.1 part of sodium benzoate,
Citric acid, honey element stir evenly in right amount, stand 12 hours, filtering, it is filling, sterilizing to get.
Embodiment 11
Chinese medicine composition of the invention has good therapeutic effect to the osteoporosis for reducing cause by estrogen.Its
In, the effect for the Chinese medicine composition being prepared with embodiment 2 is best.
120 female sd inbred rats are randomly divided into 12 groups, every group 10, respectively Normal group, castrated rats cause bone
The loose model control group of matter and test group.
Normal group: giving physiological saline, according to 10mL/kg weight to rat oral gavage.
Model control group: giving physiological saline, according to 10mL/kg weight to rat oral gavage.
Test group: by each embodiment to rat oral gavage by weight of primary crude drug amount.
Model control group implements Bilateral oophorectomy operation after being anesthetized with ether rat.Normal group is in rat plum
Ovary beside portions adipose tissue is rejected after the lower end tubal ligation of style ovary, and ovary is made to keep complete.Except normal control
Group is outer, and each group presses model group with method modeling.After modeling operation, divides basket at 12 cages rat, guarantee every group of rat body weight mean
It is at the same level, gives chow diet and feed 3 days, the 4th day formally starts to be administered.After successive administration 12 weeks, all rats are with 0.3%
The method of valeric acid barbital sodium intraperitoneal injection is anaesthetized, and mouse lies low after anesthesia and is placed in the measurement of dual intensity X borne densitometers greatly
Mouse whole body bone density (Bone mineral Density, BMD)；Mouse is put to death in etherization later, takes out complete Rat Right
Femur rubs the meat fiber tissue for going the attachment on side with the hands with gauze, exposes clean bone structure, is surveyed with dual intensity X borne densitometers
Fixed right femoral bmd；Eyeball veniplex takes blood, 3000rmin-1Centrifugation stands 10min, isolates serum, measures ALP,
StrACP, Ca, P, IL-1 β；Uterus is taken, uterus index is surveyed；Rat Right femur is taken, its maximum load and elasticity modulus are measured.
The experimental result of Normal group, model group and test group is shown in Table 2- table 4.
Table 2
1) the P < 0.05 compared with blank group；2) the P < 0.05 compared with model group.
As shown in Table 2, model control group removal ovary causes osteoporosis rat equal compared with other each group whole bodies and right thighbone density
It significantly decreases, compared with having for Normal group apparent difference (P < 0.05), and model control group and test group removal ovary
The rats in normal control group uterus index that cause osteoporosis rat more only extracts partial fat tissue has to be declined significantly, and there are aobvious
It writes sex differernce (P < 0.05), illustrates modeling success.Rats in test groups whole body bone density of the invention and right thighbone density obviously rise
Height, there are significant difference (P < 0.05), illustrates that the present invention is increasing removal ovary cause osteoporosis compared with model control group
There is good curative effect in terms of rat body and right femoral bmd.
Table 3
1) the P < 0.05 compared with blank group；2) the P < 0.05 compared with model group.
Table 4
1) the P < 0.05 compared with blank group；2) the P < 0.05 compared with model group.
Biological bone dynamics measurement is the result shows that Rat Right femur elasticity modulus, maximum load are all big after modeling as shown in Table 3
Amplitude decline, has significant difference (P < 0.05) compared with model group, and after giving pharmaceutical intervention treatment, indices are mentioned
Height, wherein it is the most significant with the performance of embodiment two, show that each embodiment can enhance the energy of femur of mature ovariectomized rats external force resistance impact
Power, wherein enhancing amplitude highest with embodiment two.
As shown in Table 4, model group is compared with for test group and Normal group, calcium in rat blood serum, phosphorus content have centainly
Decline, show that Ca, P are being lost in OP model group rats bone, but be not present significant difference, may be with body itself
Self regulating and control is related.For ALP, strACP, each embodiment can significantly reinforce ALP in Ovariectomized Rat Serum vigor (P <
0.05), reducing removal ovary causes strACP in osteoporosis rat serum horizontal (P < 0.05), wherein being compared with 2 drug effect of embodiment
Other administration groups are more significant.Compared with model group, each embodiment can significantly reduce the IL-1 β level (P in Ovariectomized Rat Serum
<0.05)。
Table 3, table 4 result further illustrate Chinese medicine composition of the invention, to by estrogen reduce caused by sclerotin dredge
Loose disease has preferable therapeutic effect.
Finally, it should be noted that the foregoing is only a preferred embodiment of the present invention, it is not intended to restrict the invention,
Although the present invention is described in detail referring to the foregoing embodiments, for those skilled in the art, still may be used
To modify the technical solutions described in the foregoing embodiments or equivalent replacement of some of the technical features.
All within the spirits and principles of the present invention, any modification, equivalent replacement, improvement and so on should be included in of the invention
Within protection scope.
Claims (10)
1. a kind of Chinese medicine composition of osteoporosis caused by treatment is reduced by estrogen, it is characterised in that: the Chinese medicine group
It closes object to be made of each bulk pharmaceutical chemicals of following parts by weight: red stilbene 6-30 parts, 3-35 parts of Rehmannia glutinosa, 3-35 parts of the fruit of glossy privet, fructus lycii 3-35
Part, 3-35 parts of radix achyranthis bidentatae.
2. Chinese medicine composition according to claim 1, it is characterised in that: the Chinese medicine composition is each by following parts by weight
Bulk pharmaceutical chemicals composition: red stilbene 12-26 parts, 9-13 parts of Rehmannia glutinosa, 9-13 parts of the fruit of glossy privet, 9-13 parts of fructus lycii and 9-13 parts of radix achyranthis bidentatae；
Preferably, the Chinese medicine composition is made of each bulk pharmaceutical chemicals of following parts by weight: 17 parts of red stilbene, 10 parts of Rehmannia glutinosa, female
Loyal son 10 parts, 10 parts of fructus lycii, 10 parts of radix achyranthis bidentatae.
3. the preparation method of Chinese medicine composition of any of claims 1 or 2, it is characterised in that: weigh respectively by weight ratio red
Stilbene, Rehmannia glutinosa, the fruit of glossy privet, fructus lycii and radix achyranthis bidentatae mixing, are added 8-20 times of the total weight water measured, decoct and extract 2-4 times, mention every time
It takes 1-2 hours, merges decoction liquor, filtration collects filtrate, is concentrated into the medicinal extract of relative density 1.26-1.35.
4. the preparation method of Chinese medicine composition pill of any of claims 1 or 2, it is characterised in that: the following steps are included:
(1) fruit of glossy privet, the crushing of red stilbene for weighing formula ratio, obtain fine powder；
(2) after the Rehmannia glutinosa, fructus lycii and the radix achyranthis bidentatae mixing that separately weigh formula ratio, the water that 8-20 times of its total weight is measured is added, decocts
It extracts 2-4 times, extracts 1-2 hours every time, merge decoction liquor, filtration collects filtrate, supernatant is taken to be concentrated under reduced pressure into relative density
1.26-1.35 medicinal extract；
(3) fine powder that step (1) obtains and the medicinal extract that step (2) obtains are uniformly mixed, press strip, pill, it is dry in 80 DEG C or less
It is dry, polishing.
The medicine of osteoporosis caused by 5. Chinese medicine composition of any of claims 1 or 2 is reduced in preparation treatment by estrogen
Application in object.
6. a kind of Chinese materia medica preparation, it is characterised in that: its effective component is Chinese medicine composition of any of claims 1 or 2.
7. Chinese materia medica preparation according to claim 6, it is characterised in that: the Chinese materia medica preparation further includes pharmaceutically acceptable
Auxiliary material.
8. Chinese materia medica preparation according to claim 7, it is characterised in that: the auxiliary material includes diluent, adhesive, described dilute
Releasing agent is one or more of starch, dextrin, lactose, maltose, microcrystalline cellulose and mannitol；Described adhesive is water
Or ethyl alcohol.
9. Chinese materia medica preparation according to claim 8, it is characterised in that: the auxiliary material further includes lubricant or preservative, institute
Stating lubricant is one or more of talcum powder, superfine silica gel powder and magnesium stearate, and the preservative is sodium benzoate, sorbic acid
One of potassium, dehydroactic acid sodium, calcium propionate, sodium Diacetate, sodium lactate, propylparaben, nisin or
It is several.
10. according to the described in any item Chinese materia medica preparations of claim 7-9, it is characterised in that: the dosage form of the Chinese materia medica preparation is
Granula, capsule, tablet, pill or liquid preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910146734.3A CN109602817B (en) | 2019-02-27 | 2019-02-27 | Traditional Chinese medicine composition for treating osteoporosis caused by estrogen deficiency |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910146734.3A CN109602817B (en) | 2019-02-27 | 2019-02-27 | Traditional Chinese medicine composition for treating osteoporosis caused by estrogen deficiency |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109602817A true CN109602817A (en) | 2019-04-12 |
| CN109602817B CN109602817B (en) | 2021-06-25 |
Family
ID=66019932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910146734.3A Active CN109602817B (en) | 2019-02-27 | 2019-02-27 | Traditional Chinese medicine composition for treating osteoporosis caused by estrogen deficiency |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109602817B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344361A (en) * | 2021-05-14 | 2022-04-15 | 天津中医药大学 | Pharmaceutical composition for preventing and treating osteoporosis |
| CN115737729A (en) * | 2022-11-24 | 2023-03-07 | 新疆医科大学 | National medicinal preparation for treating osteoporosis and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434773A (en) * | 2014-09-29 | 2016-03-30 | 熊玮 | Kidney-nourishing bone-strengthening soup for treating osteoporosis |
-
2019
- 2019-02-27 CN CN201910146734.3A patent/CN109602817B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434773A (en) * | 2014-09-29 | 2016-03-30 | 熊玮 | Kidney-nourishing bone-strengthening soup for treating osteoporosis |
Non-Patent Citations (1)
| Title |
|---|
| 张荣华等: "益骨胶囊含药血清对大鼠成骨细胞IGF-ImRNA及其蛋白表达的影响", 《中国病理生理杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344361A (en) * | 2021-05-14 | 2022-04-15 | 天津中医药大学 | Pharmaceutical composition for preventing and treating osteoporosis |
| CN114344361B (en) * | 2021-05-14 | 2023-12-15 | 天津中医药大学 | Pharmaceutical composition for preventing and treating osteoporosis |
| CN115737729A (en) * | 2022-11-24 | 2023-03-07 | 新疆医科大学 | National medicinal preparation for treating osteoporosis and preparation method thereof |
| CN115737729B (en) * | 2022-11-24 | 2023-11-03 | 新疆医科大学 | Ethnic medicine preparation for treating osteoporosis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109602817B (en) | 2021-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101940740B (en) | Chinese medicinal preparation for treating anemia | |
| CN100435831C (en) | Preparation for treating high blood pressure, high blood fat, obesity, and climacteric syndrome, and preparation method | |
| CN104208302A (en) | Fructus rosae laevigatae healthy oral solution for reducing blood fat and preparation method thereof | |
| CN107362213B (en) | Composition with bowel relaxing function and preparation method thereof | |
| CN105749179A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
| CN104352594A (en) | Jiangzhining dispersible tablets and preparation method thereof | |
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN101011562B (en) | Novel formulation of shenqiwendan decoction and production method thereof | |
| CN109602817A (en) | A kind for the treatment of is reduced the Chinese medicine composition of caused osteoporosis by estrogen | |
| CN1275634C (en) | Health tea capable of reducing blood lipid, blood viscosity and blood pressure | |
| CN106994141B (en) | Traditional Chinese medicine composition for treating constipation and preparation method thereof | |
| CN102600358A (en) | Traditional Chinese laxative medicine and product thereof | |
| CN102302609A (en) | Compound traditional Chinese drug preparation for improving subhealth | |
| CN111298021A (en) | Traditional Chinese medicine composition for treating functional constipation | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN100584359C (en) | Medicine for treating fatness and its complication | |
| CN105687788A (en) | Pharmaceutical composition capable of softening blood vessels and application thereof | |
| CN110251591A (en) | A kind of pharmaceutical composition and its preparation method and application that aided blood pressure-lowering is hypoglycemic | |
| CN1943756B (en) | A Chinese traditional medicinal composition used for treatment of hypertension and its preparation method | |
| CN105012873A (en) | Health-care blood-fat-lowering evening primrose oral liquid and preparation method thereof | |
| CN1943755B (en) | A Chinese traditional medicinal composition for treatment of hypertension and its preparation method | |
| CN106334065A (en) | Edible and medicinal traditional Chinese medicine formula used for treating gynecological diseases and having beauty effect and production process | |
| CN104857121A (en) | Drug combination for curing hyperlipidemia and application thereof | |
| CN104056234A (en) | Drug for dispelling alcohol effect and preparing method thereof | |
| CN114712466B (en) | Medicine with weight-reducing and beautifying effects and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhao Lianggong Inventor after: Feng Shilan Inventor after: Zhou Xianglin Inventor before: Feng Shilan Inventor before: Zhao Lianggong Inventor before: Zhou Xianglin |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |